When the vitreous humour shrinks, the strong attachment results in a pulling force on the retina, which may lead to visual distortion, decreased visual acuity and central blindness.
breaks down the protein fibers which cause the abnormal traction between the vitreous and the macula that cause symptomatic VMA. By dissolving these proteins, JETREA
releases the traction, and helps to complete the detachment of the vitreous from the macula.
It is estimated that around 500,000 patients in the US and five biggest markets in
alone suffer from this condition.
There are no other pharmacological treatments available for symptomatic VMA. The current approach is 'watch and wait' until a patient becomes a candidate for surgical treatment, usually at a late stage of the disease.
A patient would then receive a surgical procedure and repair of the retina. However, for many patients this is not a suitable option, as irreversible damage to the retina may have already occurred.
ThromboGenics and Alcon internal estimates
Idiopathic macular hole.
Stalmans P. Management and intervention strategies for symptomatic vitreomacular adhesions.
Koerner F & Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome.
Dugel PU, Brown DM, Humayun MS
. Symptomatic vitreomacular adhesion: diagnosis, pathologic implications, and management.
(ocriplasmin) is a truncated form of human plasmin. In the US, JETREA
is indicated for the treatment of symptomatic VMA. In
is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ≤ 400 microns. JETREA
is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and
involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
JETREA's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA was generally well tolerated with most adverse events being transient and mild in severity.